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INTRODUCTION
Increasing knowledge of the biology of multiple myeloma (MM) has unraveled significant associations between specific genetic and molecular subgroups and patients' outcome. 1 --4 Updated information has been recently published 5 confirming previous observations 6,7 on the potential prognostic impact of the immunophenotypic characteristics of bone marrow (BM) myelomatous plasma cells (MM-PCs) in MM patients. Of note, detection of CD19 þ MM-PC by multiparameter flow cytometry (MFC) in MM at diagnosis correlates with an adverse outcome, 5 although its clinical value is somehow hampered by the low frequency (4%) of CD19 þ MM cases. 5 CD19 is physically associated with CD225, CD21 and regulated by CD81, 8 --12 a tetraspanin widely expressed on B cells including mature PCs, 13, 14 which is involved in the regulation of cell growth, motility, signaling and BM homing. 8 --11,15 However, immunophenotypic studies of CD81 expression in patients with myeloma are scanty, 13, 14 and its potential prognostic value remains unknown. Here, we report on the results of a prospective analysis about the prognostic impact of the expression of CD81 in MM-PCs by MFC at diagnosis in symptomatic and high-risk smoldering MM (SMM).
PATIENTS AND METHODS Patients
The study included 230 newly diagnosed, symptomatic, elderly MM patients treated according to the Spanish GEM05465years protocol (NCT00443235: two arms of six cycles of bortezomib/melphalan/prednisone or bortezomib/thalidomide/prednisone, followed by maintenance with either bortezomib/thalidomide or bortezomib/prednisone for up to 3 years), 16 A validation set based on 325 newly diagnosed, symptomatic, transplant candidates MM patients enrolled in the Spanish GEM05o65-years trial (NCT00461747: randomized to receive induction with VBMCP/ VBAD plus bortezomib, or thalidomide/dexamethasone, or bortezomib/ thalidomide/dexamethason followed by high-dose therapy/autologous stem cell transplantation) was used. MM patients' response was assessed using the European Group for Blood and Marrow Transplant criteria. 17 Additionally, we have analyzed a total of 56 SMM patients newly diagnosed according to the International Myeloma Working Group criteria 18 and with high-risk of progression to symptomatic disease, based on the presence of at least two of the three following criteria: BM PC infiltration X10%; high M-component (immunoglobulin GX30 g/l or immunoglobulin AX20 g/l or B --J protein41 g/24 h); or X95% MM-PCs/ BMPCs plus immune paresis. The median follow-up was 32 for the MM and SMM series, respectively. All control and patient samples were collected after informed consent was obtained from each individual, according to the local ethical committees and the Helsinki Declaration.
MFC immunophenotypic studies
Erythrocyte-lysed whole-BM samples were stained using a direct immunofluorescence technique previously described in detail, 5, 19 with three four-color monoclonal antibody combinations---(fluorescein isothiocyanate/phycoerythrin/PerCP-Cy5.5/antigen-presenting cell). CD38/CD56/ CD19/CD45, CD38/CD27/CD45/CD28 and b2-microglobulin/CD81/CD38/ CD117 aimed at the identification, quantification and characterization of MM-PCs, including CD81 surface expression. DNA PC content was assessed by MFC according to standard methods, 20 through simultaneous staining for MM-PCs and DNA with CD38/CD138 (fluorescein isothiocyanate) and propidium iodide, respectively. Acquisition was performed in a FACSCalibur flow cytometer (BD Biosciences (BDB), San Jose, CA, USA) with a double-step data acquisition procedure and the CellQUEST PRO software (BDB). 5, 19 Fluorescence in situ hybridization analysis To investigate a potential correlation between both the CD81 surface protein (MFC) and the genomic mRNA expressions, we used a data set of GEP (full data available at GEO, GSE16558) that we had previously generated on a subset of 23 of the 230 MM patients and in 6 healthy adults. Expression values for each probe set were calculated using the RMAExpress program that uses the Robust Multi-Array Average algorithm. 22 Cell culture and western blotting MM cell lines (RPMI-8226, RPMI-LR5, NCI-H929, OPM-2, JJN3, MM1S, MM1R, MM144, U266, U266-DOX4, U266-LR7, SJR and MGG) were grown at 37 1C in a humidified atmosphere in the presence of 5% CO 2 --95% air in RPMI 1640 medium supplemented with 10% fetal bovine serum and antibiotics. MM cell lines were prepared for protein analysis in non-reducing conditions following standard procedures. 23 For immunoprecipitation and western blot analyses, an anti-CD81 antibody was purchased from BDB.
Statistical analyses
The Mann --Whitney U and Pearson correlation tests were used to estimate the statistical significance of differences between groups of cases and correlations between variables, respectively. Time to progression, progression-free survival (PFS) and overall survival (OS) distribution curves were plotted using the Kaplan --Meier method; the log-rank test was used to estimate the statistical significance of differences observed between curves. Figures 1c and d) . Interestingly, the presence of CD19 þ MM-PC was noted in only 12 out of the 230 (5%) patients, and all except 1 were also positive for CD81. In turn, all the remaining cases with CD81 expression (n ¼ 92) showed no reactivity for CD19. No significant differences were found in the baseline characteristics of CD81 þ (homogeneous and heterogeneous) vs CD81 À MM patients, including the pattern of cytogenetic abnormalities (data not shown). However, the percentage of MM-PCs in S-phase was found to be higher (Po0.001) in patients with CD81-positive expression (1.5% (0--6.2%)) when compared with CD81 cases (0.9% (0--6.0%)).
The results observed in patients were also confirmed in MM cell lines. Thus, we tested by MFC immunophenotyping the amount of CD81 protein expression in a panel of MM cell lines (RPMI-8226, RPMI-LR5, NCI-H929, OPM-2, JJN3, MM1S, MM1R, MM144, U266, U266-DOX4, U266-LR7, SJR and MGG). As shown in Figure 2a , 5 out of the 13 MM cell lines analyzed were homogeneously positive for CD81 (RPMI-8226, RPMI-LR5, NCI-H929, OPM-2 and JJN3) while the others exhibited no expression. These results were further validated by western blotting (Figure 2b ). When normalized to the control protein (glyceraldehyde-3-phosphate dehydrogenase), JJN3, RPMI-8226 and RPMI-LR5 revealed very high levels of CD81, H929 and OPM2 moderate while no expression was detected in the other lines. We also explored in a subgroup of patients (n ¼ 23) in which information was available, the relationship between positivity for CD81 by MFC and its genomic expression. Our results showed that the expression level of CD81 mRNA was significantly decreased (Pp0.02) in CD81 À MM cases vs healthy adults, CD81 À/ þ and CD81 þ patients, with no significant differences between this latter subgroup and healthy adults (Figure 3a) . Accordingly, we found a highly significant correlation between the expression of CD81 mRNA by GEP and the percentage of CD81 þ MM-PC by MFC (r ¼ 0.812, Po0.001; Figure 3b ). Genomic vs antigen CD81 expression in myeloma. In (a), differences in the expression of CD81 determined by GEP between MM-PCs from CD81 À (n ¼ 9), CD81 À/ þ (n ¼ 7) and CD81 þ (n ¼ 7) symptomatic MM patients at diagnosis vs normal plasma cells obtained from healthy adults. In (b), the expression level of CD81 quantified by GEP (grey bars) and the percentage of CD81 þ MM-PC determined by MFC (black bars) are plotted for each MM patient studied at diagnosis, ordered from the lowest to highest percentage of CD81 þ MM-PC (from left to right on the x-axis), with a significant correlation between GEP and MFC results.
Impact of CD81 antigen expression on patients' survival Regarding the impact of CD81 on patients' survival, cases showing CD81-positive expression showed a significant shorter PFS as compared with CD81 À patients (3-year rates of 26% vs 52%, Po0.001; Figure 4a ) without differences between CD81 þ and CD81 À/ þ cases (30 and 25% PFS at 3 years, P ¼ 0.687; Supplementary Figure 1A) . A similar picture was observed for OS between positive vs negative CD81 patients (3-year rates of 63% vs 78%, P ¼ 0.007; Figure 4b) , with no differences between the homogeneous and heterogeneous CD81 þ cases (3-year rates of 57% vs 66%, P ¼ 0.312; Supplementary Figure 1B) . Response rates after induction were lower for CD81 þ cases as compared with CD81 À (X partial response: 72% vs 88%; P ¼ 0.002 and complete remission: 18% vs 29%, P ¼ 0.06). The treatment arm did not influenced patients' outcome according to CD81 expression (data not shown).
Multivariate analysis of prognostic factors for survival in MM patients, including other baseline variables with significant influence in the univariate analysis ( Table 1 ), showed that the best combination of independent predictive parameters for PFS were: CD81 þ expression on MM-PCs and high-risk cytogenetics (t(4;14), t(14;16) and/or del(17p)); in turn for OS, CD81 þ expression, high-risk cytogenetics and elevated lactate dehydrogenase were selected. Accordingly, the immunophenotypic detection of CD81 þ vs CD81 À MM-PC was able to discriminate different risk groups not only among patients with standard-risk cytogenetics (PFS, P ¼ 0.001; Figure 5a and OS, P ¼ 0.02; Figure 5b ) but also among the high-risk cytogenetics subgroup (PFS, P ¼ 0.01; Figure 5a and OS, P ¼ 0.02; Figure 5b ). In fact, those cases displaying high-risk cytogenetics but with a CD81 À phenotype showed a PFS (Figure 5a ) and OS (Figure 5b ) similar (P40.05) to that of patients with standard-risk cytogenetics. 
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To validate the adverse impact of CD81 þ expression, we explored whether this new marker would retain its prognostic value in a series of 325 newly diagnosed, transplant candidates, symptomatic MM patients. CD81
þ cases (171 out of 325, 53%) showed shorter PFS (3-year rates of 43% vs 69%, Po0.001; Figure 4c ) and OS (3-year rates of 77% vs 90%, P ¼ 0.002; Figure 4d ) as compared with CD81
À cases (154 out of 325, 47%). Then, we investigated if CD81 þ expression could retain its independent prognostic value in the transplanted series. Our results show that in the multivariate analysis (Supplementary Table 1 ) the presence of high-risk cytogenetics, elevated lactate dehydrogenase, 415% PCs by MFC, p5% normal PCs within the BMPC compartment, and CD81 þ expression on MM-PCs remained as independent prognostic factors for PFS; in turn, for OS the presence of high-risk cytogenetics, increased lactate dehydrogenase and 415% PCs by MFC were selected (Supplementary Table 1 ).
On the basis of the poor outcome of CD81 þ expression seen in symptomatic MM patients, we then focused on the 56 high-risk SMM patients to investigate whether this new antigen could also Abbreviations: BMPC, bone marrow plasma cell; FISH, fluorescence in situ hybridization; GEM, Grupo Españ ol de MM; HR, hazard ratio; ISS, International staging system; LDH, lactate dehydrogenase; MFC, multiparameter flow cytometry; MMPC, myelomatous plasma cell; OS, overall survival; PCs: plasma cells; PFS, progression-free survival. *High-risk cytogenetics includes any t(4;14), t(14;16), and del(17p); standard-risk cytogenetics includes all other cases.
CD81 expression in myeloma B Paiva et al be a predictive marker for disease progression. Interestingly, the median time to progression to symptomatic myeloma was significantly shorter for CD81 þ SMM cases (n ¼ 32, 57%) when compared with CD81
À patients (31 months vs not reached, P ¼ 0.02; Figure 4e ).
DISCUSSION
Over the last decade, intensive scientific research has unraveled the presence of key genetic, 2,3,25,26 transcriptomic 27,28 and epigenetic 29 features that contribute to understand the pathophysiology of MM, and define patient subgroups with different outcome. 1, 4, 25, 26, 29 It has also been described that some of these features are associated with specific phenotypic profiles, 7, 30 but in contrast to other hematological malignancies, 31, 32 in MM the antigenic profile of malignant cells is not usually taken into account for patient risk stratification. 33 We have recently reported that CD19 expression in MM-PCs is an adverse prognostic marker. 5 Nonetheless, the clinical impact of CD19 assessment may be somehow hampered by the low frequency (4%) of CD19 þ MM cases. 5 The regulatory role of tetraspanin CD81 over CD19 has been elegantly demonstrated in CD81-knockout mice; 34 --36 moreover, the N-terminus and the first transmembrane regions of CD81 are also required for normal CD19 expression, 37 and more recently van Zelm et al. 12 described the first antibody deficiency syndrome caused by a mutation in the CD81 gene and consequent disruption of the CD19 complex on B cells.
In this study, we have prospectively analyzed the frequency and prognostic impact of CD81, assessed by MFC immunophenotyping in a series of 230 newly diagnosed elderly symptomatic MM patients treated according to the Spanish GEM05465years trial. Afterwards, we validated our results in an additional series of 325 newly diagnosed transplant candidates symptomatic MM patients (GEM05o65years trial); in addition we have investigated whether CD81 could be a predictive marker for disease progression in a series of 56 high-risk SMM patients. To the best of our knowledge, only two studies have reported on the expression of CD81 in patients with MM, 13, 14 with CD81 positivity being detected in 13 14 and 40% 13 of cases. Herein, we have detected the presence of CD81 þ MM-PC in approximately half of all myeloma patients. Moreover, we founded positive expression for CD81 in B40% of MM cell lines, which was further confirmed by western blotting. Given the regulatory role of CD81 over CD19 within the CD19/ CD21/CD81 complex, 8 --12 we were able to confirm that within those CD19 þ cases, all except one were also positive for CD81. However, as CD81 is upstream of CD19, as expected a significant number of patients (n ¼ 92) showed positive expression for CD81 but lacked reactivity for CD19. In addition, the expression of CD81 was also evaluated at the transcriptome and protein level, with our results showing the existence of a highly significant correlation between the phenotypic and the results derived by GEP.
The pattern of CD81 antigen expression was able to identify approximately half of symptomatic elderly MM patients with a dismal outcome based on PFS and OS; these results being further confirmed in the series of symptomatic younger (o65 years) MM patients. By multivariate analysis, CD81
þ MM-PC plus high-risk cytogenetics at diagnosis represented the best combination of independent variables for predicting both PFS and OS. In fact, the immunophenotypic detection of CD81 þ MM-PC was able to discriminate two prognostic subgroups within both standard-and high-risk cytogenetics patients; this underlies that there are still several subgroups among those define by specific cytogenetic abnormalities, and that other techniques such as MFC or GEP may contribute to improve patient risk stratification. In addition, we have found that CD81 þ SMM patients had a shorter time to progression to symptomatic disease than CD81 À patients. These results highlight the fact that even within well-defined high-risk SMM, 38, 39 the risk of progression to active myeloma is still heterogeneous and thus, efforts to individualize risk profiling would be highly valuable for tailored clinical monitoring and potential early therapeutic intervention. 40 Further investigations on the clinical value of CD81 assessment are warranted in the context of low-risk SMM and Monoclonal gammopathy of undetermined significance patients. Similarly, minimal residual disease monitoring with eight-color MFC immunophenotyping will allow longitudinal analysis of CD81 expression within the MM-PC compartment, and elucidate whether CD81 þ MM-PC represent a more chemoresistant clone. Finally, the prognostic influence of CD81 expression makes this marker a potential therapeutic target, but our preliminary results indicate that although treatment with anti-CD81 antibodies specifically decreased proliferation of CD81 þ cell lines, it did not induced ADCC or CDC (data not shown). Therefore, further studies will be required to elucidate the potential role of anti-CD81 as a therapeutic target.
In summary, our findings show the existence of a phenotypic --genomic correlation of CD81 expression in patients with myeloma. Importantly, the expression of CD81 in MM-PCs is an independent prognostic factor for patients with symptomatic MM and a marker for risk of progression in SMM. Thus, the precise mechanism of CD81 activation of MM-PCs deserves further investigations.
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